NEWS AND EVENTS
Aura Biosciences Form Clinical Advisory Board in Ocular Oncology and Strengthens Clinical Team to Prepare for Clinical Development of Lead Program in Ocular Melanoma
September 30, 2015
Aura Biosciences, a biotechnology company developing a new class of therapies to target and selectively destroy cancer cells, announced today that it has formed a Clinical Advisory Board in Ocular Oncology and bolstered its clinical development team as it prepares to initiate clinical testing of its lead program in Ocular (uveal) Melanoma.
Aura Biosciences Announce Publication Describing Selective Binding of Viral-like Particles to Cancer Cells
September 21, 2015
Aura Biosciences, a biotechnology company developing a new class of therapies to target and selectively destroy cancer cells, announced today the publication of a new paper demonstrating how its synthetic Viral-like Particles (VLP) modeled on the human papillomavirus (HPV) are able to bind uniquely to cancer cells while leaving healthy surrounding tissue unharmed.
FDA Grants Orphan Drug Designation to Aura Biosciences' Novel Treatment for Uveal Melanoma
May 21, 2015
Aura Biosciences, a biotech company developing highly tumor-targeted breakthrough therapies for rare cancers, has been granted Orphan Disease Designation by the FDA for its drug AU-011 for the treatment of Uveal Melanoma.
Aura Biosciences Want to Treat Eye cancer and Save Patients' Vision
March 5, 2015
When cancer forms in the eye the goal of treatment is to save the patient’s life first and preserve vision second. Investors are betting Aura Biosciences Inc. can do both.
March 5, 2015
Chiesi Ventures invests in rare optho-oncology company AuraBiosciences. The Boston-based company is focused on the development of drugs using tumor targeted Pseudovirions, synthetic viruses that demonstrate key targeting selectivity for solid tumors and metastases and can efficiently release target molecules within cancerous cells.